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Early prediction of IgA nephropathy progression: Proteinuria
and AOPP are strong prognostic markers.
Background. Inflammation and oxidative stress have been
incriminated in the pathogenesis of IgA nephropathy (IgAN).
The aim of the present study was to assess whether
markers reflecting these pathophysiologic processes, namely
C-reactive protein (CRP) and advanced oxidation protein prod-
ucts (AOPP), would allow—in conjunction with clinical and
histopathologic parameters—to predict disease progression.
Methods. Between 1994 and 1997, 120 adult patients with
biopsy-proven IgAN were included in a prospective cohort
study, and followed until the end of 2002 or start of dialysis. In
every patient, we determined plasma levels of CRP and AOPP.
These parameters were included, together with clinical data, in a
multivariate Cox proportional hazard regression analysis, with
halving of baseline creatinine clearance as the primary renal
end point.
Results. A total of 51 patients reached the renal end point,
including 30 who had to start dialysis. With multivariate analysis,
the most potent independent risk factors of poor renal outcome
were proteinuria ≥1 g/day [proportional hazard risk (HR) =
23.7, P = 0.0001], hypertension (HR = 8.13, P = 0.008), and
AOPP plasma level (HR = 1.09 per 10 lmol/L, P = 0.042),
whereas angiotensin II inhibitors were protective (HR = 0.19,
P = 0.001).
Conclusion. Our data support the role of oxidative stress in
the pathogenesis of IgAN and suggest that patients with pro-
teinuria ≥1 g/day should be eligible for early implemented an-
tioxidant and/or anti-inflammatory therapeutic strategies, with
AOPP plasma level as a surrogate marker to evaluate their
effects.
Immunoglobulin A nephropathy (IgAN), or Berger’s
disease, is the most common type of primary glomeru-
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lonephritis worldwide [1]. Although it was initially
thought to be a benign condition, more recent studies with
long-term follow-up have revealed that development of
progressive renal failure is frequent, and IgAN now ap-
pears to be the leading cause of end-stage renal disease
(ESRD) among primary glomerulonephritides in indus-
trialized countries, especially in Japan [2, 3].
However, IgAN outcome is highly variable between
individuals. End-stage renal failure may occur within
5 years of presentation, or conversely, more than 20 years
later [2–6]. Therefore, identification of factors predictive
of subsequent outcome at the time of presentation should
be of great interest, particularly if such factors can be al-
tered by treatment [6, 7]. Clinical and histologic parame-
ters have been identified as independent risk factors for
progression toward renal failure, especially heavy pro-
teinuria [2–4, 7, 8], arterial hypertension [2, 4], reduced
renal function at diagnosis [3, 8], and glomerular sclerosis
or tubulointerstitial scarring at renal biopsy [2, 4, 8]. How-
ever, severe histologic lesions, heavy proteinuria, and/or
elevated serum creatinine actually characterize already
advanced renal failure rather than reflect the progres-
sion rate of renal disease. Thus, indices that may allow
prediction of progression at an earlier stage of the dis-
ease should be of great interest.
Recent studies of the pathogenetic mechanisms of
IgAN have stressed the presumptive role of mediators
of inflammation, notably cytokines and oxidative stress
(reviewed in [1]). This was supported by the encouraging
results of therapeutic trials using corticosteroids [9, 10]
or antioxidants such as fish-oil extracts in both exper-
imental [11] and human IgAN [1]. Recently, advanced
oxidation protein products (AOPP) emerged as relevant
markers of oxidative stress and novel mediators of in-
flammation in renal diseases [12]. In a previous study, we
found that AOPP plasma concentrations increased with
the progression of chronic renal failure in uremic patients
with a variety of chronic renal diseases, both glomeru-
lar and nonglomerular. Moreover, AOPP were closely
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correlated with markers of monocyte activation [13], thus
suggesting that they may by themselves contribute to
the inflammatory process associated with chronic renal
failure.
The present study, performed in a large cohort of IgAN
patients, was aimed at evaluating whether proteinuria,
hypertension, and histologic scores could predict the sub-
sequent progression of IgAN, and whether elevated levels
of AOPP and C-reactive protein (CRP) were associated
with a higher rate of progression of renal disease in IgAN
patients.
METHODS
Study population
All 120 consecutive adult patients with biopsy-proven
primary IgAN cared for at our institution between
September 1994 and October 1997 were included in an
observational cohort study after giving informed consent.
Excluded from the study were patients with Henoch-
Scho¨nlein purpura, cirrhosis, or systemic lupus erythe-
matosus, and patients aged less than 15 years at the time
of renal biopsy.
Design
A single starting time (i.e., when plasma AOPP and
CRP concentrations were determined) was used in ev-
ery patient. The follow-up was extended until October
2002 so that it might last at least 5 years for each patient
of the cohort. In every patient, we recorded the demo-
graphic and clinical data, including age, gender, blood
pressure, urinary protein excretion (g/24hr), and serum
creatinine (lmol/L) at entry in the study (baseline data).
Existence or absence of at least one documented episode
of macroscopic hematuria at any time in the course of the
disease was also recorded. Proteinuria was categorized
as <1 g/24hr or ≥1 g/24hr. Hypertension was defined as a
systolic blood pressure (BP) ≥150 mm Hg and/or a dias-
tolic BP ≥90 mm Hg, or current antihypertensive therapy;
current treatment with angiotensin II (Ang II) inhibitors
[angiotensin-converting enzyme inhibitors (ACEIs) or
Ang II receptor antagonists] was also recorded.
Renal function was evaluated by the level of creati-
nine clearance (Ccr) according to the Cockcroft-Gault
formula [14], normalized for body surface area and ex-
pressed as mL/min/1.73 m2. The primary renal end point
was taken as halving of baseline Ccr. Patients who exhib-
ited a decrease in Ccr less than 50% at end of follow-up
were classified as group I, and patients whose decline in
Ccr was 50% or more were classified as group II. The
rate of progression of renal failure was expressed as the
yearly rate of decline in Ccr (Ccr, mL/min/1.73 m2/year)
between entry in the study and end of follow-up or start
of dialysis. A progression rate <3 mL/min/1.73 m2/year
defined slow progressors, whereas a progression rate ≥3
mL/min/1.73 m2/year was considered a fast progression.
Kidney biopsy samples were reviewed and semiquan-
titatively scored by one investigator (LHN). Glomerular
score (range 0 to 8) was the sum of mesangial prolifera-
tion (none = 0, focal = 1, diffuse = 2), cellular crescents,
segmental fibrosis, and global glomerular sclerosis (for
each, none = 0, <50% = 1, ≥50% = 2). Interstitial score
(0 to 4) included interstitial fibrosis and cellular infiltrate
(for both none = 0, <50% = 1, ≥50% = 2). Vascular score
(0 to 2) included sclerosis of arterioles and of interlobular
arteries (for both none = 0, presence = 1).
Laboratory determinations
CRP and AOPP were determined at baseline in all
patients. Ultrasentitive CRP, detection limit ≥0.5 mg/L,
normal range 0.5 to 2 mg/L) was determined in the serum
by enzyme-linked immunosorbent assay (ELISA) (Dade
Berhing, Marburg, Germany) as described previously
[15]. AOPP were determined in the plasma using the
semiautomated method previously devised in our labora-
tory [12]. Briefly, AOPP are measured by spectrophotom-
etry on a microplate reader (Model MR 5000; Dynatech,
Paris, France), and are calibrated with chloramine-T
(Sigma Chemical Co., St Louis, MO, USA) solutions,
which, in the presence of potassium iodide, absorb at
340 nm. In test wells, 200 lL of plasma diluted 1:5 in
phosphate-buffered saline (PBS) is placed on a 96-well
microtiter plate (Becton Dickinson Labware, Lincoln
Park, NJ, USA), and 20 lL of acetic acid is added. In
standard wells, 10 lL of 1.16 mol/L potassium iodide (KI,
Sigma Chemical Co.) is added to 200 lL of chloramine-T
solution (0 to 100 lmol/L), followed by 20 lL of acetic
acid. The absorbance of the reaction mixture is immedi-
ately read at 340 nm on the microplate reader against a
blank containing 200 lL of PBS, 10 lL of KI, and 20 lL
of acetic acid. The chloramine-T absorbance at 340 nm,
being linear within the range of 0 to 100 lmol/L, AOPP
concentrations are expressed in lmol/L of chloramine-T
equivalents.
Statistical analyses
Data are expressed as mean ± SD unless otherwise
specified. Differences in frequencies were determined by
chi-square analysis. Comparison of groups was done by
Student t test or analysis of variance (ANOVA). Gen-
der, urinary protein excretion (UPE, < or ≥l.0 g/day),
hypertension (yes/no), macroscopic hematuria (yes/no),
treatment with Ang II inhibitors (yes/no), were used
as categorical variables. The primary renal end point
was taken as halving of baseline Ccr. The Kaplan-
Meier method was applied to estimate survival proba-
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bilities, and the log-rank test was used to determine their
significance.
A first univariate Cox analysis was performed, includ-
ing the parameters related to prognosis from baseline
to renal end point. The following variables were consid-
ered: gender, age, proteinuria, macroscopic hematuria,
hypertension, Ccr, CRP, and AOPP levels. Because kid-
ney biopsy was performed at the time of study in only
56 patients, histologic scores were not entered in the Cox
analysis.
Stepwise multivariate Cox proportional hazard regres-
sion with a maximum of five terms in subset (including the
intercept) was then applied to determine the independent
relationship of all unadjusted significant variable (P <
0.10) predictors of renal end point forced into the model.
The subset selection was proceeded using a hierarchical
forward algorithm with switching, taking into account in-
teractions between the different variables. Variables were
considered significant for P ≤ 0.05 after adjustment for
all variables, and after the maximum subset size has been
reached.
All tests were performed using NCSS 2000 software
(Jerry L. Hintze, Kaysville, UT, USA).
RESULTS
Clinical and laboratory data
Of the 120 patients (96% Caucasian), 91 were males
and 29 were females (sex ratio 3.1:1). Mean age at entry
in the study (baseline) was 39.9 ± 15.5 years. The over-
all mean duration from baseline to end of follow-up was
5.4 ± 2.5 years (range 1.2 to 7.9).
By the end of the observation period, 51 patients (43%)
reached the renal end point (i.e., halved Ccr), including 30
patients who reached ESRD and were started on main-
tenance dialysis. Table 1 compares baseline clinical and
laboratory data in the 69 group I patients who retained a
preserved renal function (group I) and in the 51 patients
who reached the renal end point (halved Ccr, group II).
The sex ratio did not significantly differ between the
two groups, but age of patients was significantly higher
in group II than in group I. Urinary protein excretion
and the proportion of patients with proteinuria ≥1 g/day
were strikingly higher in group II than in group I. Many
more patients were hypertensive and more patients were
treated with Ang II inhibitors in group II than in group
I. Conversely, macroscopic hematuria was less frequent
in group II than in group I. Mean plasma creatinine was
higher, and accordingly, mean Ccr was significantly lower
in group II than in group I patients.
CRP level did not significantly differ between group I
and group II. In contrast, AOPP level was significantly
higher in group II than in group I.
Table 1. Baseline demographic, clinical, histologic, and laboratory
characteristics of IgAN patients who reached (Group II) or did not
reach (Group I) the renal end point (halving of Ccr) at end of
follow-up
Characteristic Group I Group II P value
Number of patients 69 51
Sex ratio (M/F) 2.6 4.1 0.39
Age years 36.2 ± 14.5 44.9 ± 15.7 0.0022
Urine protein 0.59 ± 0.62 2.67 ± 1.28 <0.0001
excretion g/day
Proteinuria ≥1 g/day % 18.8 96 <0.0001
Macroscopic hematuria % 53.6 31.4 0.0168
Hypertension % 40.6 96.1 <0.0001
Treatment with Ang II 37.7 74.5 <0.0001
inhibitors %
Plasma creatinine lmol/L 97 ± 22 297 ± 220 <0.0001
Creatinine clearance 79.5 ± 16.4 35.6 ± 20.2 <0.0001
mL/min/1.73m2
Follow-up duration years 5,72 ± 2.46 4.89 ± 2.55 0.76
 Ccr mL/min/1.73m2/year 1.19 ± 0.72 5.18 ± 3.02 <0.0001
 Ccr≥3 mL/min/1.73m2/ 2.9 90 <0.0001
year %
CRP mg/L 2.05 ± 2.93 2.11 ± 2.45 0.93
AOPP lmol/L 35.2 ± 26.1 69.9 ± 41.2 <0.0001
Number of kidney biopsies 40 16
Glomerular score 3.12 ± 1.45 4.37 ± 1.98 0.0049
Interstitial score 1.01 ± 0.99 2.44 + 0.73 <0.0001
Vascular score 1.28 ± 0.72 1.37 ± 0.88 0.68
In the 56 patients with kidney biopsy contemporary
with AOPP and CRP determinations, vascular scores
were not discriminant between the 40 patients who re-
tained a preserved renal function and the 16 who reached
renal end point, whereas both glomerular and interstitial
scores were significantly higher in group II than in group
I (Table 1).
Rate of IgAN progression
The rate of decline in Ccr (Ccr) was strikingly
higher in group II than in group I. In group II, 46/51
patients (90%) were fast progressors with a Ccr ≥
3 mL/min/1.73m2/year, whereas in group I, 67/69 pa-
tients (97%) had a slow progression rate with a Ccr <
3 mL/min/1.73m2/year. When analyzed in terms of slow
or fast progressors groups, distribution of urinary protein
excretion, hypertension, Ccr, CRP, and AOPP values was
very similar to that observed between group I and group
II patients stratified with respect to renal end point (data
not shown).
There was a close relationship between Ccr and uri-
nary protein excretion and AOPP level (Fig. 1).
Renal survival
By univariate Cox regression analysis (Table 2), age,
proteinuria, hypertension, use of Ang II inhibitors, Ccr,
and AOPP levels were significantly associated with
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Fig. 1. Relationships between ∆Ccr and urinary protein excretion (A)
or advanced oxidation protein products (AOPP) plasma level (B) at en-
try in the study, in 120 IgA nephropathy (IgAN) patients. Ccr, creatinine
clearance.
Table 2. Predictors of loss of renal function determined by univariate
Cox regression analysis
Risk factors HR (95%CI) P value
Gender (male) 1.84 (0.69–3.83) 0.10
Age (per 1 year) 1.02 (1.01–1.04) 0.0028
Macroscopic hematuria yes 0.71 (0.37–1.33) 0.2817
Proteinuria ≥1 g/day yes 16.41 (3.97–67.84) 0.00001
Hypertension yes 18.2 (4.40–75.23) 0.0001
Ccr (per 1mL/min/1.73 m2) 0.93 (0.91–0.95) 0.00001
Treatment with angiotensin 0.50 (0.28–0.96) 0.038
II inhibitors yes
CRP (per 1 mg/L) 0.97 (0.89–1.06) 0.5133
AOPP (per 10 lmol/L) 1.42 (1.28–1.58) 0.00001
renal outcome. These factors were first entered in a mul-
tivariate adjusted Cox regression model (Table 3). In this
model Ccr, proteinuria, and AOPP were significantly as-
sociated with renal end point. Because of the close corre-
lation between Ccr at baseline and at end of follow-up
(r = 0.91, P < 0.0001), we performed a second Cox
Table 3. Proportional hazard ratios for reaching renal endpoint
determined by multivariate Cox regression analysis
Prognostic variables HR (95%CI) P value
First model (with Ccr included)
Ccr (per 1 mL/min/1.73 m2) 0.94 (0.92–0.97) 0.0000
Proteinuria ≥1 g/day yes 7.78 (1.81–33.4) 0.0057
AOPP (per 10 lmol/L) 1.11 (1.02–1.21) 0.0305
Second model (without Ccr included)
Proteinuria ≥ 1g/day yes 23.7 (5.35–104.8) 0.0001
Hypertension yes 8.13 (1.72–38.5) 0.008
Angiotensin II inhibitors yes 0.19 (0.09–0.44) 0.001
AOPP (per 10 lmol/L) 1.09 (1.00–1.18) 0.042
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Fig. 2. Renal survival in IgA nephropathy (IgAN) patients with uri-
nary protein excretion (UPE) <1 g/day (N = 63) or ≥1 g/day (N =
57) at entry in the study. Difference between Kaplan-Meier curves is
highly significant (log-rank test, chi-square = 31.8, P < 0.00001).
regression analysis without including Ccr. In this model,
proteinuria, hypertension, and AOPP were significant
independent predictors associated with poor renal out-
come, whereas anti-Ang II use was protective. Overall,
these four factors explained 48% of the variance.
The renal survival curves from baseline to renal end
point highly significantly differed between patients with
proteinuria <1 g/day or ≥1 g/day at baseline (P < 0.0001)
(Fig. 2), and between patients with baseline plasma AOPP
level lower or higher than the median value of 40 lmol/L
(Fig. 3).
DISCUSSION
Our main conclusion is that in IgAN patients, the com-
bination of proteinuria in excess of 1 g/day, hypertension,
and disproportionate AOPP plasma level, as a marker of
oxidative stress, is predictive of progressive renal disease.
In most published studies, multivariate analysis based
on renal survivorship identified elevated serum cre-
atinine and heavy proteinuria at presentation as the
main predictors of poor outcome in adult patients. In
particular, impaired renal function at the time of renal
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Fig. 3. Renal survival in IgA nephropathy (IgAN) patients with ad-
vanced oxidation protein product (AOPP) plasma level <40 lmol/L
(N = 84) or ≥40 lmol/L (N = 36) at entry in the study. Difference
between Kaplan-Meier curves is highly significant (log-rank test, chi-
square = 24.7, P < 0.0001).
biopsy was found to be the most powerful predictive fac-
tor in a number of studies [3–5, 8, 17–21]. In these studies,
impaired renal function was defined on the basis of vari-
able threshold levels for serum creatinine ranging from
1.2 mg/dL [4, 5, 17, 22] to 1.4 to 1.5 mg/dL [2, 3, 18, 21,
23], or even as high as 1.7 mg/dL [8, 24]. However, all
such levels of serum creatinine correspond to a markedly
impaired renal function, with a Ccr already below 60 mL/
min/1.73 m2 in most cases. Therefore, as renal failure,
once established, usually relentlessly progresses toward
ESRD, the finding that impaired renal function at presen-
tation is predictive of impaired renal failure at follow-up,
as reported in most studies, is somewhat tautologic. It
would be much more relevant to detect patients at risk
of developing progressive renal failure at an earlier stage
of the disease, when Ccr is still normal or nearly normal,
and when therapeutic intervention has the best chances
of stopping the progression [1]. Proteinuria universally
appears to be the most significant, independent clinical
factor predictive of a progressive course of IgAN. The
most generally accepted risk threshold is a protein excre-
tion ≥1 g/day [4, 5, 8, 25], although other authors used
a higher threshold such as 2 g/day [18, 19, 22, 26]. Uri-
nary protein excretion in excess of 2 g/day is undoubt-
edly a strong marker of a progressive course, but such a
heavy proteinuria is infrequently present at clinical onset
of IgAN or at biopsy [5, 27]. Therefore, a proteinuria ≥
1 g/day at presentation appears to be a more sensitive
risk factor. In our cohort, proteinuria ≥1 g/day was found
by multivariate analysis to constitute the most powerful
predictive clinical factor of poor outcome. Of note, pro-
teinuria was already ≥1 g/day at clinical onset of IgAN
in virtually all of our patients with such a urinary protein
excretion at the time of study.
Hypertension has been reported to be associated with
progressive forms of IgAN [2, 17, 24]. This was confirmed
in our patients, and Ang II inhibitors were shown to have
a protective effect. A beneficial influence of Ang II in-
hibitors on the course of IgAN has also been observed by
other authors. In a short-term prospective study, ACEIs
were shown to significantly reduce urinary protein excre-
tion [28]. In a retrospective study of 115 IgAN patients
with baseline proteinuria ≥1 g/day, hypertensive patients
treated with ACEIs had a slower rate of decline in renal
function and a higher percentage of remission in pro-
teinuria than those who received other antihypertensive
drugs [29]. Likewise, in a series of chronic nondiabetic
nephropathies, including a subset of IgAN patients, ACE
inhibition conferred renoprotection [30, 31].
High histopathologic scores have been proposed as
predictive of poor outcome [2–4, 7, 8]. In our patients hav-
ing had kidney biopsy at the same time as AOPP and CRP
determinations, both glomerular and interstitial (but not
vascular) scores were higher in patients with poor renal
outcome.
A salient finding with regard to markers of inflamma-
tion and oxidative stress is that, while CRP level was
not found to reflect the severity of the disease, elevated
AOPP level was predictive of a poor renal outcome and
remained an independent risk factor in multivariate anal-
ysis. This is in keeping with our previous reports in chronic
renal failure patients showing that AOPP are not only
markers of oxidative stress, but also affect the progres-
sion of renal failure, and by themselves act as potent me-
diators of monocyte activation [13].
In our present study, patients with progressive forms
of IgAN (group II) had a lower Ccr level at baseline than
those with slow progression, and this could account for
their higher AOPP plasma concentration [13]. However,
AOPP level in fast progressors was higher than could
be expected from the Ccr reduction by itself, and thus
was disproportionately elevated. In our cohort, 65 pa-
tients had a baseline Ccr ≥60 mL/min, and were, thus,
expected to have AOPP levels within the normal range
[13]. Among them, the 14 patients with a proteinuria ≥1 g/
day had a faster progression rate than the other 51 with
proteinuria <1 g/day, and while the mean Ccr level was
close to 83 mL/min/1.73m2 in both groups, baseline AOPP
level was significantly higher in the former than in the lat-
ter (49 ± 40 lmol/L vs. 29 ± 18 lmol/L, P = 0.009).
The finding that high plasma AOPP levels closely re-
flect progressive forms of IgAN strongly suggests the role
of oxidative stress in the pathophysiology of IgAN, and is
in support of the beneficial effects of therapeutic strate-
gies aimed at reducing oxidative stress and inflamma-
tion. As a matter of fact, in rat experimental models of
IgAN, alpha tocopherol was shown to blunt the severity
of oxidative stress [32], and fish-oil to reduce the pro-
teinuria and the development of mesangial lesions [11].
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In IgAN patients, randomized trials with fish oil extracts
conducted in a large number of patients for a long time
also showed beneficial effects in terms of slowed progres-
sion of renal failure, especially in patients who initially
had a mild or moderate degree of renal dysfunction [16,
33]. Alternatively, corticosteroids have been proposed in
the treatment of IgAN, especially in severe forms with ac-
tive crescentic glomerular lesions, because of their anti-
inflammatory and immunosuppressive properties. They
were shown to lower proteinuria [10], and in some stud-
ies to also slow progression in IgAN patients with a low
initial serum creatinine level (≤120 lmol/L) [9]. A trial
is underway to evaluate the effects of combined corti-
costeroids and azathioprine [34], but no trial to date has
examined the effects of a recently proposed antioxidant
(N-acetylcysteine) [35] or an association of antioxidants
and corticosteroids.
CONCLUSION
The results of the present study validate the major pre-
dictive value of proteinuria on the renal outcome of IgAN
patients, and strongly support the role of oxidative stress
in the pathogenesis of IgAN. They also highly suggest that
IgAN patients with proteinuria ≥1 g/day and inappropri-
ately elevated plasma AOPP at the early stage of the dis-
ease may be identified as being at high risk for progression
and should be considered for active therapy. Long-term
prospective randomized studies involving a large num-
ber of IgAN patients with still preserved or mildly im-
paired renal function will allow the assessment of whether
serial determination of AOPP may be used as a sur-
rogate marker for evaluating the effect of therapeutic
strategies.
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